Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study
Tempei Otsubo,1 Yoshinori Watanabe,2,3 Seiji Hongo,3 Mikichika Inoue,4 Kimiko Akimoto,4 Ken Murakami,5 Ryutaro Takahashi,6 Toshiaki Kikuchi7 1Department of Psychiatry, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan; 2Himorogi Psychiatric Institute, Tokyo, Japan; 3Nanko...
Enregistré dans:
| Auteurs principaux: | Otsubo T, Watanabe Y, Hongo S, Inoue M, Akimoto K, Murakami K, Takahashi R, Kikuchi T |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2018
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/20da93dc94904d95baef838f0972b627 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
par: Kishi T, et autres
Publié: (2017) -
Formulation and Development of Oral Fast-Dissolving Films Loaded with Nanosuspension to Augment Paroxetine Bioavailability: In Vitro Characterization, Ex Vivo Permeation, and Pharmacokinetic Evaluation in Healthy Human Volunteers
par: Ahmed Hassen Elshafeey, et autres
Publié: (2021) -
Effects of personality on the association between paroxetine plasma concentration and response
par: Tomita T, et autres
Publié: (2018) -
Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro/In Vivo Evaluation
par: Soraia Silva, et autres
Publié: (2021) -
A single‐center, open‐label, randomized cross‐over study to evaluate the pharmacokinetics and bioavailability of once‐daily prolonged‐release formulations of tacrolimus in de novo liver transplant recipients
par: Uta Herden, et autres
Publié: (2021)